First-ever clinical guidelines tackle the rising threat of medetomidine in the drug supply

A veterinary sedative is now a major public health crisis. Medetomidine, first detected in the unregulated opioid supply in 2021, has exploded in prevalence — reaching up to 90% nationally by December 2025, with the heaviest concentrations in the Northeast and Midwest. In response, ASAM has released its first clinical guidance to help emergency and addiction care teams identify and treat patients exposed to this adulterant.

The challenge? Medetomidine doesn't play by the usual rules. Naloxone — the go-to overdose reversal drug — has no effect on medetomidine, meaning patients may remain sedated even after treatment. Withdrawal symptoms like extreme tachycardia and dangerously high blood pressure often don't respond to typical withdrawal medications, and cases can escalate from mild to severe without warning.

Key Takeaways:

• Alpha-2 agonists (e.g., IV dexmedetomidine) are recommended for withdrawal, often at higher-than-typical doses
• Moderate-to-severe cases require hospital or ICU-level care; mild cases need nurse-monitored outpatient settings
• Standard toxicology screens don't detect medetomidine, making clinical diagnosis and local drug supply monitoring essential
• ASAM urges Medicare, Medicaid, and other payers to cover intensive care levels for medetomidine withdrawal

Why it matters: With medetomidine now pervasive in the drug supply and no rapid point-of-care test available, clinicians need updated protocols now. This guidance gives frontline teams a critical roadmap for a crisis that's only getting worse.